BioTuesdays

Category - Feature

Feature

BioSyent to target international markets

By Len Zehr BioSyent (OTC:BIOYF; TSX-V:RX) is actively building its international pharmaceutical sales and marketing business, adding products licensed and sold internationally to products already being shipped from...

August 30, 2016
Feature

In conversation with Ben Haynor

By Len Zehr As a senior research analyst with Feltl & Co. for the past six years, Ben Haynor ranked second in the May 2013 Wall Street Journal Best on the Street publication in the Medical Equipment and Supplies...

August 16, 2016
Feature

Triumvira targeting cancer with customized T cells

By Len Zehr Closely-held Triumvira Immunologics is developing a novel platform to engineer the immune system’s T cells to attack cancer using proprietary T Cell-Antigen Couplers (TACs). “TACs were designed to use the...

July 26, 2016
Feature

In conversation with Dr. Paul Lem

By Len Zehr As CEO and a co-founder of Spartan Bioscience, Dr. Paul Lem has led the closely-held company through FDA and Health Canada approval of the Spartan RX CYP2C19 System, a breakthrough technology that provides...

July 19, 2016
Feature

Braeburn taking path as pill-free pharma company

By Len Zehr Closely-held Braeburn Pharmaceuticals, which in late May received FDA approval to market the first ever six-month implant of buprenorphine for opioid dependence, is developing a portfolio of long-acting...

July 12, 2016
Feature

Merus Labs moving up the value chain

By Len Zehr After an 18-month company transformation under new CEO, Barry Fishman, Merus Labs International (NASDAQ:MSLI; TSX:MSL) is now ready to in-license new pharmaceutical products, in addition to optimizing...

July 5, 2016
Feature

Antibe to have Phase 2 pain data by third quarter

By Len Zehr Antibe Therapeutics (OTCQB:ATBPF; TSX-V:ATE) expects to have data by the third quarter this year from a small Phase 2 study of its naproxen derivative, ATB-346, in patients with osteoarthritis in the knee...

June 21, 2016